Fresenius Medical Care Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fresenius Medical Care (FMS).

Price Target Range — 7 Quarters

Analyst Consensus — 4 Analysts

3Hold

1Sell

Consensus RatingMarket Perform# Analysts4Avg. Consensus PT$25Upside to Avg. PT+15.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Truist Securities	David Macdonald	PT Cut	Hold	$25→$24
Aug 6, 2026	Bernstein	Lisa Clive	PT Raise	Market Perform	$26→$26
Sep 2, 2025	UBS	Graham Doyle	Downgrade	Neutral→Sell	—
May 12, 2025	Truist Securities	David Macdonald	PT Raise	Hold	$25→$30
Jan 6, 2025	Truist Securities	David Macdonald	PT Raise	Hold	$23→$25
Oct 7, 2024	Truist Securities	David Macdonald	PT Raise	Hold	$22→$23
Jul 31, 2024	Truist Securities	David Macdonald	PT Cut	Hold	$24→$22
May 15, 2024	Truist Securities	David Macdonald	PT Raise	Hold	$21→$24
Apr 15, 2024	Truist Securities	David Macdonald	PT Cut	Hold	$24→$21
Nov 24, 2023	HSBC	Sezgi Oezener	Upgrade	Reduce→Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24

Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:FMS) with a Hold and lowers the price target from $25 to $24.

Benzinga Newsdesk

PRO
Bernstein Maintains Market Perform on Fresenius Medical Care, Raises Price Target to $25.8

Bernstein analyst Lisa Clive maintains Fresenius Medical Care (NYSE:FMS) with a Market Perform and raises the price target from $25.5 to $25.8.

Benzinga Newsdesk

This Fortinet Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

PRO
UBS Downgrades Fresenius Medical Care to Sell

UBS analyst Graham Doyle downgrades Fresenius Medical Care (NYSE:FMS) from Neutral to Sell.

Benzinga Newsdesk

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch.

Vandana Singh

PRO
Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $30

Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:FMS) with a Hold and raises the price target from $25 to $30.

Benzinga Newsdesk

Fresenius Medical Care AG

뉴스

파트너 / 기고자

벤징가 글로벌

Fresenius Medical Care Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24

PRO
Bernstein Maintains Market Perform on Fresenius Medical Care, Raises Price Target to $25.8

This Fortinet Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

PRO
UBS Downgrades Fresenius Medical Care to Sell

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

PRO
Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $30

People Also Watch

People Also Watch

Fresenius Medical Care AG

뉴스

파트너 / 기고자

벤징가 글로벌

Fresenius Medical Care Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24

PROBernstein Maintains Market Perform on Fresenius Medical Care, Raises Price Target to $25.8

This Fortinet Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

PROUBS Downgrades Fresenius Medical Care to Sell

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

PROTruist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $30

People Also Watch

People Also Watch

PRO
Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $24

PRO
Bernstein Maintains Market Perform on Fresenius Medical Care, Raises Price Target to $25.8

PRO
UBS Downgrades Fresenius Medical Care to Sell

PRO
Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $30